Trials / No Longer Available
No Longer AvailableNCT05582083
Managed Access Program for Momelotinib in Myelofibrosis
Managed Access Program for Momelotinib in Patients With a Diagnosis of Intermediate or High-risk Myelofibrosis (MF), Including Primary Myelofibrosis (PMF) or Secondary Myelofibrosis (Post- Polycythemia Vera/ Essential Thrombocytopenia (PV/ET)), With Anaemia
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Compassionate use access to Momelotinib/GSK3070785 for eligible participant with diagnosis of intermediate or high-risk myelofibrosis (MF), including primary myelofibrosis (PMF) or secondary myelofibrosis (post- polycythemia vera/ essential thrombocytopenia (PV/ET)), with anemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Momelotinib | Momelitinib available as tablets. |
Timeline
- First posted
- 2022-10-17
- Last updated
- 2023-11-08
Source: ClinicalTrials.gov record NCT05582083. Inclusion in this directory is not an endorsement.